Lundbeck to divest non-strategic investments to the Lundbeck Foundation
"We aim to build Lundbeck into the world's leading pharmaceutical company in the field of neurology, and activities that do not add any strategic value will therefore be divested. We are pleased that this divestment will strengthen the Lundbeck Foundation in its efforts to become an active life science partner," says Lundbeck's CFO Anders Götzsche.
For the Lundbeck Foundation, the transaction underlines the foundation's new investment strategy, the cornerstone of which is incremental investments in life science.
The shares in LifeCycle Pharma are traded at a price of DKK 18 per share, corresponding to a total price of DKK 276 million, providing Lundbeck with a profit of approximately DKK 124 million relative to the carrying amount of the shares. The profit will be recognised as revenue in Lundbeck's financial statements for the first quarter of 2009.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.